things that have been done from a public policy point of view that have enhanced investment in biomedical r & d. would i point to the orphan drug act which is a great example, where it was recognize that had r & d credit for investing in orphan drugs as well as exclusivity for developing orphan drugs ensure that there is a better economic equation for making those investments, and we have seen dramatic increases and huge productivity of investment in orphan drugs. it's a great example. i think we've seen already some of the fruits of the gain act which was part of the fda safety innovation act in 2012 where exclusivity was provided for antibiotics that address resistant infections and we've seen a resurgence of private investment in that extremely important area so there's just a couple of examples. what are some specific examples of what we can do going forward? well, one is to continue to enhance this dialogue about empowering the regulators with the tools to help speed development of the most important new therapies and, you know, it really was fda who came forward and said we need break